

ACT Onco[®] + Report

PATIENT		
Name: 范淑玲		Patient ID: 25405883
Date of Birth: Sep 04, 1958		Gender: Female
Diagnosis: Lung adenocarcinoma		
ORDERING PHYSICIAN		
Name: 趙恆勝醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11176311A	Collection site: Lymph node	Type: FFPE tissue
Date received: May 16, 2022	Lab ID: AA-22-02570	D/ID: NA

ABOUT ACT Onco[®]+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) (≤ 15 nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

SUMMARY FOR ACTIONABLE VARIANTS

VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
EGFR L858R	Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib	-	-

VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
	Not detected	

Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criteria for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

ACT Onco[®] + Report

TESTING RESULTS

VARIANT(S) WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
<i>EGFR</i>	L858R	28.3%
<i>LRP1B</i>	C354*	30.2%
<i>TP53</i>	*394fs	43.9%

- Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr13	<i>RB1</i>	Heterozygous deletion	1
Chr18	<i>SMAD4</i>	Heterozygous deletion	1
Chr22	<i>CHEK2, NF2</i>	Heterozygous deletion	1
Chr5	<i>TERT</i>	Amplification	6*
Chr7	<i>EZH2</i>	Amplification	6*
Chr3	<i>BCL6, PIK3CA, PRKCI</i>	Amplification	7*
Chr7	<i>CARD11</i>	Amplification	7*

* Increased gene copy number was observed.

- Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

- Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	6.3 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

Note:

- Variant(s) enlisted in the SNV table may currently exhibit no relevance to treatment response prediction. Please refer to INTERPRETATION for more biological information and/or potential clinical impacts of the variants.
- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 40% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco[®] to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at ≥ 7.5 mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is $< 30\%$.

ACT Onco[®] + Report

THERAPEUTIC IMPLICATIONS TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
Level 1		
EGFR L858R	Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib	sensitive

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
1	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
2	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
3A	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
3B	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
4	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

ACT Onco[®] + Report

IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

- Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
LRP1B loss-of-function	Likely associated with BETTER response to ICIs
EGFR aberration	Likely associated with WORSE response to ICIs

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

OTHERS

Pharmacogenomic implication

Gene	Detection Site	Genotype	Drug Impact	Level of Evidence*
UGT1A1	rs4148323	AG	Irinotecan-based regimens	Level 1B

Clinical Interpretation:

Patients with the AG genotype and cancer who are treated with irinotecan-based regimens may have an increased risk of diarrhea and neutropenia as compared to patients with the GG genotype, or a decreased risk of diarrhea and neutropenia compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of diarrhea and neutropenia.

* Level of evidence was defined by PharmGKB (<https://www.pharmgkb.org/page/clinAnnLevels>)

Level 1A: Clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation.

Level 1B: Clinical annotations describe variant-drug combinations with a high level of evidence supporting the association but no variant-specific prescribing guidance in an annotated clinical guideline or FDA drug label.

Level 2A: Variants in Level 2A clinical annotations are found in PharmGKB's Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely.

Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

ACT Onco[®] + Report

VARIANT INTERPRETATION

EGFR L858R

Biological Impact

The EGFR gene encodes for the Epidermal Growth Factor Receptor, a receptor tyrosine kinase which binds to its ligands, including Epidermal Growth Factor (EGF) and Transforming Growth Factor- α (TGF- α), activates downstream signaling pathways, including the canonical oncogenic MAPK and PI3K/AKT/mTOR signaling cascades^[1]. Increased EGFR activity by mutations and/or amplification of the EGFR gene has been described in a wide range of cancers, such as lung, brain, colorectal and head and neck cancer^[2]. Mutations in the kinase domain of EGFR are commonly observed in non-small cell lung cancer (NSCLC), resulting in a constitutively activated form of the receptor^[3]. On the other hand, in the brain and colorectal cancers, the most prevalent EGFR alteration is copy number amplification that results in receptor overexpression^[4].

EGFR L858R is a missense mutation at position 858, located in exon 21, which encodes part of the kinase domain, from a leucine to an arginine residue^[5]. The two most common EGFR alterations, L858R mutation and exon 19 deletions can result in constitutive activation of signal transduction pathways, leading to cell proliferation or anti-apoptosis without ligand binding^[6].

Therapeutic and prognostic relevance

There is accumulated clinical evidence suggested that patients with MDM2/MDM4 amplification or EGFR aberrations exhibited poor clinical outcome and demonstrated a significantly increased rate of tumor growth (hyper-progression) after receiving immune checkpoint (PD-1/PD-L1) inhibitors therapies^[7] (Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376).

The first- and second-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), dacomitinib, erlotinib, gefitinib and afatinib have been approved by the U.S. Food and Drug Administration (FDA) as the first-line treatment in non-small cell lung cancer (NSCLC) patients whose tumor carries EGFR exon 19 deletion or L858R mutation^{[8][9][10]}, as detected by a U.S. FDA-approved test. A Phase III clinical trial (NCT01774721) show that dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-positive NSCLC^[8]. Another Phase III clinical trial (NCT00949650) demonstrated that median progression-free survival (PFS) among lung cancer patients with exon 19 deletion or L858R EGFR mutation (n=308) was 13.6 months for afatinib and 6.9 months for chemotherapy. The EGFR T790M mutation has been demonstrated to confer resistance to TKIs (dacomitinib, gefitinib, erlotinib, and afatinib) in preclinical and clinical studies^{[11][12][13][14]}.

Osimertinib, a third-generation irreversible EGFR-TKI that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations, has been approved by the U.S. FDA for NSCLC patient harboring T790M mutation-positive tumor^{[15][16][17]}. Results from a double-blind, Phase 3 trial further showed that osimertinib significantly demonstrated longer PFS than standard EGFR-TKIs (18.9 months vs. 10.2 months) in previously untreated EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC^[18].

LRP1B C354*

Biological Impact

Low-density lipoprotein receptor protein 1B (LRP1B) is a surface protein involved in the receptor-mediated endocytosis and signal transduction (UniProtKB). LRP1B is known as a tumor suppressor and was reported among the top 10 most significantly deleted genes across 3312 human cancer specimens^[19]. Besides deletions, mutations and epigenetic silencing of LRP1B have been previously reported in lung adenocarcinoma^[20], hepatocellular carcinoma^[21], renal cell carcinoma^[22], thyroid cancer^[23], gastric cancer^[24], esophageal squamous cell carcinoma^[25], and colon cancer^[26].

C354* mutation results in a premature truncation of the LRP1B protein at amino acid 354 (UniProtKB). This mutation

ACT Onco[®] + Report

is predicted to lead to a loss of LRP1B function, despite not having characterized in the literature.

Therapeutic and prognostic relevance

The prevalence of genetic alterations (mostly loss-of-function mutations) in the LRP1B gene was significantly higher in patients who responded to PD-1 blockade than that of the non-responders (11 vs. 1 mutations, 34% vs. 3%, respectively, $P = 0.008$). Moreover, an analysis of TCGA dataset showed that melanomas patients with LRP1B mutations had significantly higher tumor mutational load when compared with those without LRP1B mutations^{[27][28]}, as well as prolonged survival in response to immunotherapy. In addition, a retrospective study has shown that pathogenic and likely pathogenic alterations of LRP1B gene are associated with higher ORR, improved PFS and OS in ICI treated advanced or metastatic malignancies (DOI: 10.1200/JCO.2020.38.15_suppl.3007)^[29]. However, there were several limitations in this study, including limited sample size and unmeasured confounders. Therefore, further clinical validations are still needed.

A retrospective study has demonstrated that deletion or downregulation of LRP1B showed significant correlation with acquired chemotherapy resistance in patients with high-grade serous ovarian cancer (HGSC). Functional studies also showed that reducing LRP1B expression was sufficient to reduce the sensitivity of HGSC cell lines to liposomal doxorubicin but not to doxorubicin^[30]. Furthermore, deletion of LRP1B has been reported to be significantly associated with poor progression-free survival (6.4 m vs. 10.1 m) and overall survival (13.4 m vs. 17.8 m) in patients with glioblastoma^[31].

TP53 *394fs

Biological Impact

TP53 encodes the p53 protein, a crucial tumor suppressor that orchestrates essential cellular processes including cell cycle arrest, senescence and apoptosis^[32]. TP53 is a proto-typical haploinsufficient gene, such that loss of a single copy of TP53 can result in tumor formation^[33].

*394fs mutation results in a premature truncation of the p53 protein at amino acid 394 (UniProtKB). This mutation is predicted to lead to a loss of p53 function, despite not having characterized in the literature.

Therapeutic and prognostic relevance

Despite having a high mutation rate in cancers, there are currently no approved targeted therapies for TP53 mutations. A phase II trial demonstrated that Wee1 inhibitor (AZD1775) in combination with carboplatin was well tolerated and showed promising anti-tumor activity in TP53-mutated ovarian cancer refractory or resistant (< 3 months) to standard first-line therapy (NCT01164995)^[34].

In a retrospective study (n=19), advanced sarcoma patients with TP53 loss-of-function mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with pazopanib^[35]. Results from another Phase I trial of advanced solid tumors (n=78) demonstrated that TP53 hotspot mutations are associated with better clinical response to the combination of pazopanib and vorinostat^[36].

Advanced solid tumor and colorectal cancer patients harboring a TP53 mutation have been shown to be more sensitive to bevacizumab when compared with patients harboring wild-type TP53^{[37][38][39]}. In a pilot trial (n=21), TP53-negative breast cancer patients demonstrated increased survival following treatment with bevacizumab in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel)^[40]. TP53 mutations were correlated with poor survival of advanced breast cancer patients receiving tamoxifen or primary chemotherapy^{[41][42]}. In a retrospective study of non-small cell lung cancer (NSCLC), TP53 mutations were associated with high expression of VEGF-A, the primary target of bevacizumab, offering a mechanistic explanation for why patients exhibit improved outcomes after bevacizumab treatment when their tumors harbor mutant TP53 versus wild-type TP53^[43].

ACT Onco[®] + Report

BCL6 Amplification

Biological Impact

BCL6 (B-cell CLL/lymphoma 6) gene encodes a zinc-finger transcriptional repressor which plays essential roles in lymphocyte differentiation, cell cycle progression and apoptosis^{[44][45][46][47]}. BCL6 amplification and/or rearrangement were frequently observed in diffuse large B-cell Lymphoma (DLBCL)^{[48][47]}, non-Hodgkin's lymphoma^[49], and nodular lymphocyte-predominant Hodgkin Lymphoma^[50]. Besides, overexpression of BCL6 has been identified in gallbladder carcinoma^[51], and ovarian cancer^{[52][53]}.

Therapeutic and prognostic relevance

In a retrospective study, BCL6 gene amplification could cause BCL6 mRNA upregulation and overexpression of BCL6 protein in muscle-invasive urinary bladder urothelial carcinoma (UBUC) patients. BCL6 gene amplification and overexpression of BCL6 protein were associated with poor prognosis in UBUC. The UBUC patients with high BCL6 expression level had poor disease-specific and metastasis-free survivals^[54].

CARD11 Amplification

Biological Impact

CARD11 (caspase recruitment domain 11) gene encodes a cytoplasmic scaffold protein of the CARD11/BCL10/MALT1 (CBM) complex which plays essential roles in regulating apoptosis and NF-κB activation in response to upstream stimuli^{[55][56]}. CARD11 gain-of-function mutations are frequently detected in human diffuse large B-cell lymphoma (DLBCL)^[57] and cutaneous squamous cell carcinoma^[58]. Moreover, CARD11 gene amplification has been observed in a significant proportion of DLBCL^[59]. Biochemical assays revealed that enforced expression of CARD11/BCL10/MALT1 is essential for transformation of B-cell and survival of DLBCL cell^[60].

Therapeutic and prognostic relevance

Retrospective studies have shown that high CARD11 expression or CARD11 gene amplification was associated with poor survival in diffuse large B cell lymphoma (DLBCL)^{[61][59]}.

CHEK2 Heterozygous deletion

Biological Impact

The checkpoint kinase 2 (CHEK2 or CHK2) gene encodes a serine/threonine protein kinase involved in transducing DNA damage signals that are required for both the intra-S phase and G2/M checkpoints^[62]. CHEK2 heterozygosity has been shown to cause haploinsufficient phenotypes that can contribute to tumorigenesis through inappropriate S phase entry, accumulation of DNA damage during replication, and failure to restrain mitotic entry^{[63][64]}. CHEK2 aberrations are associated with glioblastoma, breast, ovarian, prostate, colorectal, gastric, thyroid, and lung cancers^{[65][66][67][68][69]}.

Therapeutic and prognostic relevance

In May 2020, the U.S. FDA approved olaparib for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in homologous recombination repair (HRR) genes, including BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L, and progressed following prior treatment with enzalutamide or abiraterone acetate^[70].

In addition, CHEK2 has been determined as an inclusion criterion for the trials evaluating rucaparib efficacy in ovarian cancer or prostate cancer (NCT03533946)^{[71][72]}, niraparib efficacy in melanoma (NCT03925350), pancreatic cancer (NCT03553004), prostate cancer (NCT02854436), and any malignancy, except prostate (NCT03207347), and talazoparib efficacy in HER2-negative breast cancer (NCT02401347), prostate cancer (NCT03148795), and lung cancer (NCT03377556), respectively.

ACT Onco[®] + Report

In a phase 2 trial, two prostate cancer patients harboring CHEK2 homozygous deletion was enrolled. One of the two patients had a response to olaparib^[73].

EZH2 Amplification

Biological Impact

EZH2, a catalytic component of the Polycomb repressive complex 2 (PRC2) and a histone methyltransferase, catalyzes tri-methylation of histone H3 at lysine 27 (H3K27) to regulate gene expression. Through modulating critical genes expression, EZH2 promotes cell survival, proliferation, differentiation, epithelial-to-mesenchymal transition, invasion and drug resistance of cancer cells^{[74][75][76][77]}. EZH2 gain-of-function mutations or overexpression is found in various malignancies^[78], such as lymphoma^[79], prostate cancer^[80], non-small cell lung carcinoma^[81], ovarian cancer^[82], and breast cancer^[83]. On the other hand, recurrent inactivating deletion, frameshift, nonsense and missense mutations in EZH2 also occur in myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)^{[84][85]}, and early T cell precursor acute lymphoblastic leukemia (ETP-ALL)^[86].

Therapeutic and prognostic relevance

On January, 2020 FDA has approved tazemetostat, an EZH2 inhibitor in patients with histologically confirmed, metastatic or locally advanced epithelioid sarcoma. Additionally, tazemetostat has been approved in patients with relapsed or refractory (R/R) follicular lymphoma (FL) that tumors are positive for EZH2 mutations (Y646S/H/C/F/N, A682G, and A692V)(Study E7438-G000-101, NCT01897571) on June, 2020. Several studies showed that EZH2 overexpression enhances chemoresistance in small cell lung cancer^[87], head and neck squamous cell carcinoma (HNSCC)^[88] and glioblastoma^[89]. However, there is evidence suggested that loss of EZH2 induces resistance to multiple drugs in acute myeloid leukemia^[90]. Furthermore, low expression of EZH2 was found to be associated with poor progression-free survival and overall survival in patients with colorectal cancer and treated with anti-EGFR therapies^[91].

Results from a meta-analysis (n = 9444) showed that high EZH2 expression was significantly associated with poorer prognosis in patients with breast cancer, lung cancer, colorectal cancer, digestive cancer, gynecological cancer, and urinary cancer^[92].

A systematic analysis of cases in TCGA demonstrated that amplification of EZH2, which correlates with mRNA upregulation, is frequently occurred across patients with melanoma. Additionally, melanoma patients with EZH2 activating mutations, amplification, or high mRNA expression level had a shorter median overall survival compared to patients with normal EZH2 status (2.2 years and 3.0 years, respectively). Patients with high EZH2 mRNA levels also showed shorter survival in comparison to those who have low EZH2 mRNA levels (median OS: 2.2 years and 4.0 years, respectively)^[93].

NF2 Heterozygous deletion

Biological Impact

The neurofibromin (NF2) gene encodes the protein Merlin, a tumor suppressor that functions as a negative regulator of the PI3K/AKT/mTOR pathway^{[94][95][96]}. NF2 is a haploinsufficient tumor suppressor gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions^[97]. Inactivation germline mutations in the NF2 are associated with the hereditary neurofibromatosis type 2, a disorder characterized by the growth of noncancerous tumors in the nervous system^{[94][98]}. Somatic mutations or deletion of NF2 are frequently observed in human cancers, including 20-50% of pleural mesotheliomas^[99], 6% papillary renal cell carcinoma, 5% pancreas cancer, and 4% melanoma (cbioPortal; June 2015), and less frequently in other cancers^[100].

ACT Onco[®] + Report

Therapeutic and prognostic relevance

Genomic alterations with activating effects on the mTOR signaling pathway have been identified to confer sensitivity to everolimus across multiple cancer types^{[101][102][103][104]}. There are at least two case studies indicating the clinical efficacy of everolimus in bladder cancer and urothelial carcinoma^{[105][106]}, both harboring NF2 truncating mutations. Preclinical evidence has shown the efficacy of MEK1/2 inhibitor selumetinib in KRAS-mutant thyroid cancer model with NF2 loss^[107].

Analysis of afatinib-plus-cetuximab-resistant biopsy specimens revealed a loss-of-function alteration in genes that modulate mTOR signaling pathway, including NF2 and TSC1^[108].

PIK3CA Amplification

Biological Impact

The PIK3CA gene encodes the catalytic subunit (p110α) of phosphatidylinositol 3-kinase (PI3K) that plays a key role in the PI3K/AKT signaling pathway and is involved in the regulation of cellular functions such as proliferation, metabolism and protein synthesis, angiogenesis and apoptosis. PIK3CA has long been described as an oncogene and the PIK3CA gene amplification, deletion, and mutations have been reported in a wide range of cancers, including colorectal, breast, brain, liver, ovarian, stomach and lung cancers^{[109][110][111][112]}. Mutations located in the exon 9 that encodes the PI3K helical (like E542K, E545K) and the exon 20 that encodes the catalytic/kinase domain (like H1047R, H1047L, H1047Y) have been shown to result in the constitutively activated mutant, which could enhance downstream signaling and oncogenic transformation in vitro and in vivo^{[110][113][114][115]}.

Therapeutic and prognostic relevance

Results of a phase I study (n=60) showed that one platinum-refractory epithelial ovarian cancer patient with PTEN loss and PIK3CA amplification had a partial response to PI3K inhibitor pictilisib (GDC-0941)^[116].

In a preclinical study, buparlisib (BKM120) exerted antitumor activity in lung squamous cell carcinoma cells overexpressing wild-type PIK3CA in culture^[117]. Other preclinical studies of triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma, ovarian cancer, lung small cell carcinoma, and PIK3CA-amplified cell lines were sensitive to PI3K inhibitors pictilisib^[118], BEZ235^[119], pilaralisib^[120], and PIK3CA/PIK3CD inhibitor PF-4989216^[121], respectively.

PIK3CA amplification is a biomarker predicting ovarian cancer lack of response to taxane- and platinum-based chemotherapy in ovarian cancer patients^[122].

PIK3CA amplification is associated with poor prognosis among patients with gastric cancer^[123], esophageal squamous cell carcinoma^[124], and non-lymph node metastatic head and neck squamous cell carcinoma^[125].

PRKCI Amplification

Biological Impact

The PRKCI gene encodes a member of the atypical protein kinase C (PKC). PKCs are a family of lipid-dependent serine/threonine kinases that represent a branch of the AGC kinase group which are central components of many signaling pathways that regulate diverse cellular functions including proliferation, cell cycle, differentiation, survival, cell migration, and polarity^{[126][127][128]}. PRKCI resides on chromosome 3q26, one of the most frequently amplified genomic regions in human cancers, including cervical, head and neck, lung squamous and serous ovarian cancers^{[129][130][131][132]}. PKCi is frequently overexpressed in the majority of tumor types^[133]. As reviewed in^{[134][133][135]}, PKCi is required for multiple aspects of the transformed phenotype and appears to participate in the initiation, progression and metastatic stages of cancer.

ACT Onco® + Report

Therapeutic and prognostic relevance

In NSCLC, the PB1-PB1 interaction between PKCi and Par6 is required for the transformed phenotype and Rac1 activation^[136]. A high throughput screen for small molecular weight compounds identified gold-containing compounds such as aurothioglucose (ATG), aurothiomalate (ATM) (FDA-approved for treatment of rheumatoid arthritis patients), and auranofin (ANF) as selective and potent inhibitors of PKCi and Par6 binding^[137]. Phase I studies suggested that ATM is well tolerated in patients with NSCLC and ovarian cancer (NCT00575393). However, currently, there is no FDA-approved PKCi inhibitor for patients with cancer.

Increased PRKCI gene copy number and/or increased PKCi protein expression level are associated with decreased progression-free survival and overall survival in various cancer types, including lung^[130], pancreatic cancer^[138], cholangiocarcinoma^[139], ovarian cancer^{[131][140]}. Moreover, a correlation between PKCi expression and prostate cancer recurrence was reported^[141].

RB1 Heterozygous deletion

Biological Impact

The Retinoblastoma (RB1) gene encodes a tumor suppressor that negatively regulates the cell cycle, cell division, and DNA replication^[142]. Loss-of-function RB1 could lead to unregulated cell division and growth, abrogation of multiple mechanisms that safeguard against cellular transformation, and tumorigenesis^[143]. RB1 has also been implicated as a haploinsufficient tumor suppressor with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions^{[144][145][146]}. Deletion or inactivating mutation of RB1 is found in a number of tumors, including lung, prostate, bladder, breast cancers and sarcomas. RB1 mutations are found in approximately half of all retinoblastoma cases^[147].

Therapeutic and prognostic relevance

A deleterious mutation in one or more of the three DNA repair genes ATM, RB1, and FANCC predicted pathologic response and better overall survival to cisplatin-based chemotherapy for muscle-invasive bladder cancer patients^[148]. High RB loss was found to be associated with improved pathologic clinical response in breast cancer patients treated with 5-fluorouracil/adriamycin/cytosine (FAC), T/FAC, and Taxane/Adriamycin neoadjuvant therapy^[149].

Clinical and experimental data suggested that a non-functional retinoblastoma pathway is associated with resistance to tamoxifen in breast cancer^{[150][151]}.

Acquired RB1 mutations were found in hormone receptor positive breast cancer patients who developed resistance to palbociclib or ribociclib treatment^[152]. Preclinical data also showed that knockdown of RB1 would impair antitumor activity of CDK4/6 inhibitor, abemaciclib^[153].

Two large-scale genome-sequencing projects have identified a high prevalence of mutations in TP53 and RB1 in small cell lung cancer (SCLC)^{[154][155]}. Analyses of repeat biopsy samples from patients with EGFR-mutant adenocarcinoma that had transformed to the SCLC subtype have revealed that 100% of these patients have loss of RB1 and may be the alteration that induces this non-small-cell to small-cell transformation^{[151][156]}.

ACT Onco[®] + Report

SMAD4 Heterozygous deletion

Biological Impact

The SMAD family member 4 (SMAD4) gene encodes a transcription factor that acts as a downstream effector in the TGF- β signaling pathway. Upon phosphorylated and activated by serine-threonine receptor kinase, Smad4 is the Co-Smad which recruits other activated R-Smad proteins to the Smad transcriptional complex and regulate TGF- β -targeted genes^[157]. Smad4 has been identified as a haploinsufficient gene with one copy loss may lead to a weak protein expression and is insufficient to execute its original physiological function^[158]. SMAD4 germline mutations are associated with juvenile polyposis syndrome (JPS)^{[159][160][161][162]}. Somatic mutations of SMAD4 are commonly observed in pancreatic cancer^[163], colorectal cancer (CRC)^{[161][164][165]}, and less frequently seen in other cancers such as lung adenocarcinoma^[166], head and neck cancer^{[167][168]}, and cutaneous squamous cell carcinoma^[169].

Therapeutic and prognostic relevance

In Chinese patients with metastatic colorectal cancer, SMAD4 or NF1 mutations are suggested as a potential biomarker for poor prognosis to cetuximab-based therapy^[170]. Preclinical data demonstrated that depletion of SMAD4 by shRNA knockdown increased clonogenic survival and cetuximab resistance in HPV-negative head and neck squamous cell carcinoma cells^[171].

SMAD4 is also suggested as a predictive marker for 5-fluorouracil-based chemotherapy in colorectal cancer (CRC)^{[172][173]}. CRC patients with normal SMAD4 diploidy exhibited three-fold higher benefit of 5-FU/mitomycin-based adjuvant therapy when compared with those with SMAD4 deletion^[174].

Results from clinical and meta-analyses showed that loss of SMAD4 in CRC, pancreatic cancer was correlated with poor prognosis^{[175][176][177][178][179][180][181][182]}. In cervical cancer patients, weak cytoplasmic SMAD4 expression and absent nuclear SMAD4 expression were shown to be significantly associated with poor disease-free and overall 5-year survival^[183].

TERT Amplification

Biological Impact

The TERT gene encodes the catalytic subunit of telomerase, an enzyme that maintains telomere length and genomic integrity^[184]. Upregulation of TERT promotes cancer development and progression via modulation of Wnt-catenin and nuclear factor kappa B signaling^{[185][186]}, and mitochondrial RNA processing^[187]. Activating mutations in the TERT promoter have been identified in a number of cancer types including melanoma, hepatocellular carcinoma, urothelial carcinoma, medulloblastoma, and glioma whereas TERT gene amplification is implicated in lung cancer, cervical cancer, breast cancer, Merkel cell carcinoma, neuroblastoma and adrenocortical carcinoma^{[188][189][190][191][192]}.

Therapeutic and prognostic relevance

Imetelstat (GRN163L), a telomere inhibitor which has been shown to inhibit cell proliferation in various cancer cell lines and tumor xenografts is currently in clinical trials^[184].

TERT gene amplification is an independent poor prognostic marker for disease-free survival in non-small cell lung cancer (NSCLC) and breast cancer^{[193][194][195]}.

ACT Onco[®] + Report

US FDA-APPROVED DRUG(S)

Afatinib (GILOTRIF)

Afatinib acts as an irreversible covalent inhibitor of the ErbB family of receptor tyrosine kinases, including epidermal growth factor receptor (EGFR) and erbB-2 (HER2). Afatinib is developed and marketed by Boehringer Ingelheim under the trade name GILOTRIF (United States) and GIOTRIF (Europe).

- FDA Approval Summary of Afatinib (GILOTRIF)

LUX-Lung 8 ^[196] NCT01523587	Non-small cell lung carcinoma (Approved on 2016/04/15)
	EGFR Del19/L858R
	Afatinib vs. Erlotinib [PFS(M): 2.4 vs. 1.9]
LUX-Lung 3 ^[197] NCT00949650	Non-small cell lung carcinoma (Approved on 2013/07/13)
	EGFR Del19/L858R
	Afatinib vs. Pemetrexed + cisplatin [PFS(M): 11.1 vs. 6.9]

Dacomitinib (VIZIMPRO)

Dacomitinib is an oral kinase inhibitor that targets EGFR. Dacomitinib is developed and marketed by Pfizer under the trade name VIZIMPRO.

- FDA Approval Summary of Dacomitinib (VIZIMPRO)

ARCHER 1050 ^[8] NCT01774721	Non-small cell lung carcinoma (Approved on 2018/09/27)
	EGFR Del 19/ L858R
	Dacomitinib vs. Gefitinib [PFS(M): 14.7 vs. 9.2]

Erlotinib (TARCEVA)

Erlotinib is a small molecule, reversible inhibitor of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase. Erlotinib is developed by OSI Pharmaceuticals, Genentech and Roche, and marketed by Astellas Pharm Global Development under the trade name TARCEVA.

- FDA Approval Summary of Erlotinib (TARCEVA)

RELAY NCT02411448	Non-small cell lung carcinoma (Approved on 2020/05/29)
	EGFR exon 19 deletion or exon 21 (L858R)
	Erlotinib + ramucirumab vs. Erlotinib + placebo [PFS(M): 19.4 vs. 12.4]
EURTAC ^[198] NCT00446225	Non-small cell lung carcinoma (Approved on 2013/05/14)
	Exon 19 Del/Exon 21 substitution (L858R)
	Erlotinib vs. Cisplatin + gemcitabine or cisplatin + docetaxel or carboplatin + gemcitabine or carboplatin + docetaxel [PFS(M): 10.4 vs. 5.2]
PA.3 ^[199] NCT00026338	Pancreatic cancer (Approved on 2005/11/02)
	-
	Gemcitabine vs. Placebo [OS(M): 6.4 vs. 6]

ACT Onco[®] + Report

Everolimus (AFINITOR)

Everolimus, a derivative of sirolimus, works as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and blocks mTORC1-mediated downstream signals for cell growth, proliferation, and survival. Everolimus is developed and marketed by Novartis under the trade name AFINITOR.

- FDA Approval Summary of Everolimus (AFINITOR)

RADIANT-4 ^[200] NCT01524783	Lung or gastrointestinal neuroendocrine tumor (Approved on 2016/02/26)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 3.9]
BOLERO-2 ^[201] NCT00863655	Breast cancer (Approved on 2012/07/20)
	ER+/HER2- Everolimus + exemestane vs. Placebo + exemestane [PFS(M): 7.8 vs. 3.2]
EXIST-2 NCT00790400	Tuberous sclerosis complex (tsc)-associated renal angiomyolipoma (Approved on 2012/04/26)
	- Everolimus vs. Placebo [ORR(%): 41.8 vs. 0]
RADIANT-3 ^[202] NCT00510068	Pancreatic neuroendocrine tumor (Approved on 2011/05/05)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 4.6]
EXIST-1 ^[203] NCT00789828	Subependymal giant cell astrocytoma (Approved on 2010/10/29)
	- Everolimus vs. Placebo [ORR(%): 35.0]
RECORD-1 ^[204] NCT00410124	Renal cell carcinoma (Approved on 2009/05/30)
	- Everolimus vs. Placebo [PFS(M): 4.9 vs. 1.9]

Gefitinib (IRESSA)

Gefitinib is a small molecule inhibitor of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase. Gefitinib is developed and marketed by AstraZeneca under the trade name IRESSA.

- FDA Approval Summary of Gefitinib (IRESSA)

IFUM ^[205] NCT01203917	Non-small cell lung carcinoma (Approved on 2015/07/13)
	Exon 19 Del/Exon 21 substitution (L858R)
	Gefitinib [ORR(%): 50.0]

Niraparib (Zejula)

Niraparib is an oral, small molecule inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1 and -2 (PARP-1, -2). Niraparib is developed and marketed by Tesaro under the trade name ZEJULA.

- FDA Approval Summary of Niraparib (Zejula)

PRIMA NCT02655016	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2020/04/29)
	- Niraparib vs. Placebo [PFS (overall population)(M): 13.8 vs. 8.2]

ACT Onco[®] + Report

QUADRA ^[206] NCT02354586	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2019/10/23)
	HRD-positive (defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability)
	Niraparib [ORR(%): 24.0, DOR(M): 8.3]
NOVA ^[207] NCT01847274	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/03/27)
	-
	Niraparib vs. Placebo [PFS (overall population)(M): 11.3 vs. 4.7]

Olaparib (LYNPARZA)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name LYNPARZA.

- FDA Approval Summary of Olaparib (LYNPARZA)

OlympiA NCT02032823	Her2-negative high-risk early breast cancer (Approved on 2022/03/11)
	gBRCA
	Olaparib vs. Placebo [invasive disease-free survival (IDFS)(M):]
PROfound ^[70] NCT02987543	Prostate cancer (Approved on 2020/05/19)
	ATMm, BRCA1m, BRCA2m, BARD1m, BRIP1m, CDK12m, CHEK1m, CHEK2m, FANCLm, PALB2m, RAD51Bm, RAD51Cm, RAD51Dm, RAD54Lm
	Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5]
PAOLA-1 ^[208] NCT02477644	Ovarian cancer (Approved on 2020/05/08)
	HRD-positive (defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability)
	Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7]
POLO ^[209] NCT02184195	Pancreatic adenocarcinoma (Approved on 2019/12/27)
	Germline BRCA mutation (deleterious/suspected deleterious)
	Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8]
SOLO-1 ^[210] NCT01844986	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2018/12/19)
	Germline or somatic BRCA-mutated (gBRCAm or sBRCAm)
	Olaparib vs. Placebo [PFS(M): NR vs. 13.8]
OlympiAD ^[211] NCT02000622	Breast cancer (Approved on 2018/02/06)
	Germline BRCA mutation (deleterious/suspected deleterious) HER2-negative
	Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2]
SOLO-2/ENGOT-Ov21 ^[212] NCT01874353	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/08/17)
	gBRCA+
	Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5]
Study19 ^[213] NCT00753545	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/08/17)
	-
	Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8]
Study 42 ^[214] NCT01078662	Ovarian cancer (Approved on 2014/12/19)
	Germline BRCA mutation (deleterious/suspected deleterious)
	Olaparib [ORR(%): 34.0, DOR(M): 7.9]

ACT Onco[®] + Report

Osimertinib (TAGRISSO)

Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) for patients with tumors harboring EGFR T790M mutation. Osimertinib is developed and marketed by AstraZeneca under the trade name TAGRISSO.

- FDA Approval Summary of Osimertinib (TAGRISSO)

ADAURA NCT02511106	Non-small cell lung carcinoma (Approved on 2020/12/18)
	EGFR exon 19 deletions or exon 21 L858R mutations
	Osimertinib vs. Placebo + adjuvant chemotherapy [DFS(M): NR vs. 19.6]
FLAURA ^[18] NCT02296125	Non-small cell lung carcinoma (Approved on 2018/04/18)
	EGFR Del19/L858R
	Osimertinib vs. Gefitinib or erlotinib [PFS(M): 18.9 vs. 10.2]
AURA3 ^[215] NCT02151981	Non-small cell lung carcinoma (Approved on 2017/03/30)
	EGFR T790M+
	Osimertinib vs. Chemotherapy [PFS(M): 10.1 vs. 4.4]
AURA ^[17] NCT01802632	Non-small cell lung carcinoma (Approved on 2015/11/13)
	EGFR T790M+
	Osimertinib [ORR(%): 59.0]

Rucaparib (RUBRACA)

Rucaparib is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1, -2 and -3 (PARP-1, -2, -3). Rucaparib is developed and marketed by Clovis Oncology under the trade name RUBRACA.

- FDA Approval Summary of Rucaparib (RUBRACA)

TRITON2 NCT02952534	Prostate cancer (Approved on 2020/05/15)
	gBRCA+, sBRCA
	Rucaparib [ORR(%): 44.0, DOR(M): NE]
ARIEL3 ^[71] NCT01968213	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2018/04/06)
	All HRD tBRCA
	Rucaparib vs. Placebo [PFS (All)(M): 10.8 vs. 5.4, PFS (HRD)(M): 13.6 vs. 5.4, PFS (tBRCA)(M): 16.6 vs. 5.4]
ARIEL2 ^[216] NCT01482715, NCT01891344	Ovarian cancer (Approved on 2016/12/19)
	Germline and/or somatic BRCA mutation
	Rucaparib [ORR(%): 54.0]

ACT Onco[®] + Report

Talazoparib (TALZENNA)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2. Talazoparib is developed and marketed by Pfizer under the trade name TALZENNA.

- FDA Approval Summary of Talazoparib (TALZENNA)

EMBRACA ^[217] NCT01945775	Breast cancer (Approved on 2018/10/16)
	Germline BRCA mutation (deleterious/suspected deleterious) HER2-negative
	Talazoparib vs. Chemotherapy [PFS(M): 8.6 vs. 5.6]

Temsirolimus (TORISEL)

Temsirolimus is a soluble ester of sirolimus (rapamycin, brand-name drug Rapamune) and functions as an inhibitor of mammalian target of rapamycin complex (mTORC). The inhibitory molecular mechanism is similar to Everolimus. Temsirolimus is developed by Wyeth Pharmaceuticals and marketed by Pfizer under the trade name TORISEL.

- FDA Approval Summary of Temsirolimus (TORISEL)

[218] NCT00065468	Renal cell carcinoma (Approved on 2007/05/30)
	-
	Temsirolimus vs. Ifn- α [OS(M): 10.9 vs. 7.3]

D=day; W=week; M=month

ACT Onco[®] + Report

ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit <https://clinicaltrials.gov> to search and view for a complete list of open available and updated matched trials.

No trial has been found.

ACT Onco[®] + Report


SUPPLEMENTARY INFORMATION OF TESTING RESULTS DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
EGFR	L858R	21	c.2573T>G	NM_005228	COSM6224	28.3%	2846
LRP1B	C354*	8	c.1062T>A	NM_018557	-	30.2%	1499
TP53	*394fs	11	c.1181del	NM_000546	-	43.9%	852

- Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



ACT Onco[®] + Report

OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
ADAMTS16	R956Q	19	c.2867G>A	NM_139056	COSM6593950	11.9%	1284
ADAMTS16	P966L	19	c.2897C>T	NM_139056	-	6.7%	553
ATR	Splice region	-	c.1885+7G>A	NM_001184	-	74.6%	808
FLT1	D1108Y	25	c.3322G>T	NM_002019	-	40.8%	566
IL6	L193F	5	c.577C>T	NM_000600	-	31.8%	318
KMT2D	L4552Q	40	c.13655T>A	NM_003482	-	21.8%	381
LCK	E176D	7	c.528G>C	NM_005356	-	75.8%	1870
LRP1B	A1384S	25	c.4150G>T	NM_018557	-	13.3%	1404
MUC16	M9492I	3	c.28476G>T	NM_024690	-	19.8%	504
PAX8	T158M	5	c.473C>T	NM_003466	-	39.0%	1133
RAD54L	P15H	2	c.44C>A	NM_003579	COSM464702	14.4%	1197
RB1	L647F	19	c.1939C>T	NM_000321	COSM6995432	22.9%	249
RB1	S644F	19	c.1931C>T	NM_000321	-	24.1%	261


Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

ACT Onco[®] + Report

TEST DETAILS

SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: May 2022
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11176311A
- Collection site: Lymph node
- Examined by: Dr. Chien-Ta Chiang
 1. The percentage of viable tumor cells in total cells in the whole slide (%): 35%
 2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 35%
 3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
 4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
 5. Additional comment: NA
- Manual macrodissection: Not performed
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

RUN QC

- Panel: ACTOnco[®]+

DNA test

- Mean Depth: 981x
- Target Base Coverage at 100x: 94%

RNA test

- Average unique RNA Start Sites per control GSP2: 184

ACT Onco[®] + Report

LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

NEXT-GENERATION SEQUENCING (NGS) METHODS

DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage ≥ 25 , allele frequency $\geq 5\%$ and actionable variants with allele frequency $\geq 2\%$ were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at $100\times \geq 85\%$ with a mean coverage $\geq 500\times$.

Variants reported in Genome Aggregation database with $> 1\%$ minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:

Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation ≥ 0.3 were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco[®] to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to ≥ 7.5 mutations per megabase (Muts/Mb); TMB-Low corresponds to < 7.5 Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is $< 30\%$.

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in > 400 genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

ACT Onco[®] + Report

RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be ≥ 10 .

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2 ≥ 3 ; (2) Number of supporting reads spanning the fusion junction ≥ 5 ; (3) Percentage of supporting reads spanning the fusion junction $\geq 10\%$; (4) Fusions annotated in Quiver Gene Fusion Database.

DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

Variant Analysis:

醫檢師張筑芃 博士
Chu-Yuan Chang Ph.D.
檢字第 020115 號



Sign Off

醫檢師張筑芃 博士
Chu-Yuan Chang Ph.D.
檢字第 020115 號



ACT Onco[®] + Report

GENE LIST SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMP1R1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTX	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBKB	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLCO1B1*
SLCO1B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOC1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

*Analysis of copy number alterations NOT available.

FUSION


ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1
-----	------	------	-------	-------	-------	-----	------	-------	-------	-------	-----	------

POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS




ACT Onco[®] + Report



1: Olaparib, Niraparib, Rucaparib, Talazoparib

Receptor Tyrosine Kinase/Growth Factor Signalling



1: Gefitinib, Afatinib, Erlotinib, Osimertinib, Dacomitinib; 2: Afatinib

ACT Onco[®] + Report

DISCLAIMER

法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

ACT Onco[®] + Report

REFERENCE

1. PMID: 18045542; 2007, Cell;131(5):1018
SnapShot: EGFR signaling pathway.
2. PMID: 10880430; 2000, EMBO J;19(13):3159-67
The ErbB signaling network: receptor heterodimerization in development and cancer.
3. PMID: 15329413; 2004, Proc Natl Acad Sci U S A;101(36):13306-11
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
4. PMID: 11426640; 2000, Oncogene;19(56):6550-65
The EGF receptor family as targets for cancer therapy.
5. PMID: 17318210; 2007, Nat Rev Cancer;7(3):169-81
Epidermal growth factor receptor mutations in lung cancer.
6. PMID: 22263017; 2010, J Thorac Dis;2(1):48-51
Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.
7. PMID: 28351930; 2017, Clin Cancer Res;23(15):4242-4250
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
8. PMID: 28958502; 2017, Lancet Oncol;18(11):1454-1466
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
9. PMID: 24868098; 2014, Oncologist;19(7):774-9
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
10. PMID: 23982599; 2013, Drugs;73(13):1503-15
Afatinib: first global approval.
11. PMID: 27912760; 2016, J Biomed Sci;23(1):86
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
12. PMID: 15728811; 2005, N Engl J Med;352(8):786-92
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
13. PMID: 26862733; 2016, Oncotarget;7(11):12404-13
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
14. PMID: 29410323; 2018, J Thorac Oncol;13(5):727-731
EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.
15. PMID: 24893891; 2014, Cancer Discov;4(9):1046-61
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
16. PMID: 27071706; 2016, J Hematol Oncol;9():34
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
17. PMID: 25923549; 2015, N Engl J Med;372(18):1689-99
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
18. PMID: 29151359; 2018, N Engl J Med;378(2):113-125
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

ACT Onco[®] + Report

19. PMID: 20164920; 2010, Nature;463(7283):899-905
The landscape of somatic copy-number alteration across human cancers.
20. PMID: 18948947; 2008, Nature;455(7216):1069-75
Somatic mutations affect key pathways in lung adenocarcinoma.
21. PMID: 23788652; 2013, Genome Res;23(9):1422-33
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.
22. PMID: 23521319; 2013, Cancer Sci;104(7):817-25
Down expression of LRP1B promotes cell migration via RhoA/Cdc42 pathway and actin cytoskeleton remodeling in renal cell cancer.
23. PMID: 21057533; 2011, Oncogene;30(11):1302-17
Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells.
24. PMID: 20095042; 2010, Genes Chromosomes Cancer;49(5):412-24
Aberrant methylation impairs low density lipoprotein receptor-related protein 1B tumor suppressor function in gastric cancer.
25. PMID: 15172977; 2004, Cancer Res;64(11):3741-7
Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma.
26. PMID: 28408316; 2017, Exp Cell Res;357(1):1-8
Down-regulation of LRP1B in colon cancer promoted the growth and migration of cancer cells.
27. PMID: 27671167; 2016, Cancer Immunol Res;4(11):959-967
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
28. PMID: 31164891; 2019, Front Immunol;10():1113
Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.
29. PMID: 33653800; 2021, J Immunother Cancer;9(3):
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
30. PMID: 22896685; 2012, Cancer Res;72(16):4060-73
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
31. PMID: 26428308; 2015, J Neurol Sci;358(1-2):440-3
LRP1B deletion is associated with poor outcome for glioblastoma patients.
32. PMID: 24739573; 2014, Nat Rev Cancer;14(5):359-70
Unravelling mechanisms of p53-mediated tumour suppression.
33. PMID: 21125671; 2011, J Pathol;223(2):137-46
Haplo-insufficiency: a driving force in cancer.
34. PMID: 27998224; 2016, J Clin Oncol;34(36):4354-4361
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
35. PMID: 26646755; 2016, Ann Oncol;27(3):539-43
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
36. PMID: 25669829; 2015, Ann Oncol;26(5):1012-8
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
37. PMID: 27466356; 2016, Mol Cancer Ther;15(10):2475-2485

ACT Onco[®] + Report

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.

38. PMID: 23670029; 2013, Oncotarget;4(5):705-14
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.
39. PMID: 17145525; 2006, Semin Oncol;33(5 Suppl 10):S8-14
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
40. PMID: 21399868; 2011, Int J Oncol;38(5):1445-52
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
41. PMID: 20549698; 2011, Int J Cancer;128(8):1813-21
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
42. PMID: 10786679; 2000, Cancer Res;60(8):2155-62
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
43. PMID: 25672981; 2015, Cancer Res;75(7):1187-90
VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.
44. PMID: 9019154; 1995, Cell Growth Differ;6(12):1495-503
The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
45. PMID: 10981963; 2000, Immunity;13(2):199-212
BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.
46. PMID: 18452090; 2008, Leuk Lymphoma;49(5):874-82
Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.
47. PMID: 15202519; 2003, Leuk Lymphoma;44 Suppl 3():S5-12
Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6.
48. PMID: 24887414; 2014, PLoS One;9(6):e98169
Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.
49. PMID: 8167331; 1994, Blood;83(9):2423-7
LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients.
50. PMID: 24678684; 2014, Arch Pathol Lab Med;138(4):538-42
Fluorescence immunophenotyping and interphase cytogenetics (FICTION) detects BCL6 abnormalities, including gene amplification, in most cases of nodular lymphocyte-predominant Hodgkin lymphoma.
51. PMID: 24114011; 2014, Tumour Biol;35(2):1417-26
BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma.
52. PMID: 25628935; 2015, Am J Cancer Res;5(1):255-66
BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer.
53. PMID: 28671040; 2017, Tumour Biol;39(7):1010428317711655
High expressions of BCL6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer.
54. PMID: 31903146; 2020, Theranostics;10(2):707-724
Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.
55. PMID: 11278692; 2001, J Biol Chem;276(15):11877-82
CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members

ACT Onco[®] + Report

that interact with BCL10 and activate NF-kappa B.

56. PMID: 26260210; 2015, Mol Immunol;68(2 Pt C):546-57
TCR signaling to NF-kB and mTORC1: Expanding roles of the CARMA1 complex.
57. PMID: 18323416; 2008, Science;319(5870):1676-9
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
58. PMID: 26212909; 2015, Am J Pathol;185(9):2354-63
Novel CARD11 Mutations in Human Cutaneous Squamous Cell Carcinoma Lead to Aberrant NF-kB Regulation.
59. PMID: 22397314; 2012, Leuk Lymphoma;53(10):1971-7
Role of nuclear factor-kB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.
60. PMID: 26668357; 2015, Proc Natl Acad Sci U S A;112(52):E7230-8
Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-kB and JNK activation.
61. PMID: 26876250; 2016, Zhonghua Xue Ye Xue Za Zhi;37(1):30-4
[Expression and prognostic value of CARD11 in diffuse large B cell lymphoma].
62. PMID: 21088254; 2011, Clin Cancer Res;17(3):401-5
Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability.
63. PMID: 15261141; 2004, Cancer Cell;6(1):45-59
Chk1 is haploinsufficient for multiple functions critical to tumor suppression.
64. PMID: 15539958; 2005, Cell Cycle;4(1):131-9
Chk1 is essential for tumor cell viability following activation of the replication checkpoint.
65. PMID: 23296741; 2013, Fam Cancer;12(3):473-8
The risk of gastric cancer in carriers of CHEK2 mutations.
66. PMID: 24713400; 2014, Hered Cancer Clin Pract;12(1):10
A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland.
67. PMID: 25583358; 2015, Int J Cancer;137(3):548-52
CHEK2 mutations and the risk of papillary thyroid cancer.
68. PMID: 12052256; 2002, Breast Cancer Res;4(3):R4
Mutation analysis of the CHK2 gene in breast carcinoma and other cancers.
69. PMID: 15125777; 2004, Mol Cancer;3():14
CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer.
70. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
71. PMID: 28916367; 2017, Lancet;390(10106):1949-1961
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
72. PMID: 32086346; 2020, Clin Cancer Res;26(11):2487-2496
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
73. PMID: 26510020; 2015, N Engl J Med;373(18):1697-708
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
74. PMID: 24967960; 2014, Cell Death Dis;5():e1298
EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting

ACT Onco[®] + Report

the epithelial-mesenchymal transition.

75. PMID: 25633838; 2015, Cancer Lett;359(2):275-87
EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer.
76. PMID: 22505648; 2012, Cancer Res;72(12):3091-104
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
77. PMID: 23759596; 2013, Cell Cycle;12(13):2042-50
EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.
78. PMID: 26845405; 2016, Nat Med;22(2):128-34
Targeting EZH2 in cancer.
79. PMID: 20081860; 2010, Nat Genet;42(2):181-5
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
80. PMID: 23636686; 2013, Protein Cell;4(5):331-41
EZH2, an epigenetic driver of prostate cancer.
81. PMID: 24097870; 2013, Clin Cancer Res;19(23):6556-65
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
82. PMID: 29726819; 2018, Mol Cancer Ther;17(3):591-602
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.
83. PMID: 25017254; 2014, Oncol Rep;32(3):1101-7
Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1 α , refines relapse risk and predicts poor outcome for breast cancer.
84. PMID: 20601953; 2010, Nat Genet;42(8):722-6
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.
85. PMID: 20601954; 2010, Nat Genet;42(8):665-7
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
86. PMID: 30080177; 2018, J Clin Invest;128(9):3872-3886
Ezh2 loss propagates hypermethylation at T cell differentiation-regulating genes to promote leukemic transformation.
87. PMID: 28196596; 2017, Cancer Cell;31(2):286-299
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.
88. PMID: 26604082; 2016, Oral Oncol;52():66-74
EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
89. PMID: 25400745; 2014, Int J Clin Exp Pathol;7(10):6662-70
Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
90. PMID: 27941792; 2017, Nat Med;23(1):69-78
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
91. PMID: 28147317; 2017, Oncotarget;8(11):17810-17818
EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.
92. PMID: 26683709; 2016, Oncotarget;7(4):4584-97
Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis.
93. PMID: 26936398; 2016, Neoplasia;18(2):121-32

ACT Onco[®] + Report

Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.

94. PMID: 25893302; 2016, Oncogene;35(5):537-48
Role of Merlin/NF2 inactivation in tumor biology.
95. PMID: 19451229; 2009, Mol Cell Biol;29(15):4235-49
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.
96. PMID: 19451225; 2009, Mol Cell Biol;29(15):4250-61
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
97. PMID: 17655741; 2007, Brain Pathol;17(4):371-6
Role of NF2 haploinsufficiency in NF2-associated polyneuropathy.
98. PMID: 19545378; 2009, Orphanet J Rare Dis;4():16
Neurofibromatosis type 2 (NF2): a clinical and molecular review.
99. PMID: 21642991; 2011, Nat Genet;43(7):668-72
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
100. PMID: 24393766; 2014, Oncotarget;5(1):67-77
NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.
101. PMID: 27091708; 2016, J Clin Oncol;34(18):2115-24
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
102. PMID: 26503204; 2016, J Clin Oncol;34(5):419-26
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
103. PMID: 24833916; 2014, Breast Cancer (Dove Med Press);6():43-57
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.
104. PMID: 26859683; 2016, Oncotarget;7(9):10547-56
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
105. PMID: 22923433; 2012, Science;338(6104):221
Genome sequencing identifies a basis for everolimus sensitivity.
106. PMID: 25630452; 2015, Eur Urol;67(6):1195-1196
Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.
107. PMID: 26359368; 2015, Cancer Discov;5(11):1178-93
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.
108. PMID: 24813888; 2014, Cell Rep;7(4):999-1008
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.
109. PMID: 16449998; 2006, Br J Cancer;94(4):455-9
Mutation of the PIK3CA oncogene in human cancers.
110. PMID: 15016963; 2004, Science;304(5670):554
High frequency of mutations of the PIK3CA gene in human cancers.
111. PMID: 12094235; 2002, Nat Rev Cancer;2(7):489-501
The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

ACT Onco[®] + Report

112. PMID: 9916799; 1999, Nat Genet;21(1):99-102
PIK3CA is implicated as an oncogene in ovarian cancer.
113. PMID: 16168105; 2005, Breast Cancer Res;7(5):R609-16
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
114. PMID: 16432179; 2006, Proc Natl Acad Sci U S A;103(5):1475-9
Cancer-specific mutations in PIK3CA are oncogenic in vivo.
115. PMID: 23411347; 2013, Trends Pharmacol Sci;34(3):149-53
Novel approaches to inhibitor design for the p110 β phosphoinositide 3-kinase.
116. PMID: 25370471; 2015, Clin Cancer Res;21(1):77-86
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
117. PMID: 26013318; 2015, Mol Cancer Ther;14(8):1916-27
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
118. PMID: 27196766; 2016, Mol Cancer Ther;15(7):1545-56
Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.
119. PMID: 28446642; 2017, Mol Cancer Ther;16(7):1257-1268
Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
120. PMID: 25637314; 2015, Mol Cancer Ther;14(4):931-40
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
121. PMID: 24240111; 2014, Clin Cancer Res;20(3):631-43
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
122. PMID: 19029838; 2009, Cancer Biol Ther;8(1):21-6
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
123. PMID: 22292935; 2012, BMC Cancer;12():50
Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.
124. PMID: 27095573; 2016, Oncotarget;7(21):30691-701
PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
125. PMID: 22994622; 2012, BMC Cancer;12():416
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
126. PMID: 9601053; 1998, Biochem J;332 (Pt 2):281-92
The extended protein kinase C superfamily.
127. PMID: 19273207; 2009, Front Biosci (Landmark Ed);14():2386-99
Protein kinase C isoforms: Multi-functional regulators of cell life and death.
128. PMID: 20094051; 2010, Nat Rev Mol Cell Biol;11(2):103-12
PKC and the control of localized signal dynamics.
129. PMID: 24231509; 2014, Biochem Pharmacol;88(1):1-11
Atypical protein kinase C α as a human oncogene and therapeutic target.
130. PMID: 16204062; 2005, Cancer Res;65(19):8905-11

ACT Onco[®] + Report

Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer.

131. PMID: 16116079; 2005, Proc Natl Acad Sci U S A;102(35):12519-24
Atypical PKC*iota* contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.
132. PMID: 17990328; 2008, Genes Chromosomes Cancer;47(2):127-36
Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma.
133. PMID: 20945390; 2011, J Cell Physiol;226(4):879-87
Protein kinase C*i* expression and oncogenic signaling mechanisms in cancer.
134. PMID: 18167314; 2008, Adv Enzyme Regul;48():166-78
Protein kinase C isozymes as therapeutic targets for treatment of human cancers.
135. PMID: 17956262; 2007, Biochem Soc Trans;35(Pt 5):996-1000
Targeting the oncogenic protein kinase C*iota* signalling pathway for the treatment of cancer.
136. PMID: 18427549; 2008, Oncogene;27(35):4841-53
Matrix metalloproteinase-10 is a critical effector of protein kinase C*iota*-Par6*alpha*-mediated lung cancer.
137. PMID: 16452237; 2006, Cancer Res;66(3):1767-74
A novel small-molecule inhibitor of protein kinase C*iota* blocks transformed growth of non-small-cell lung cancer cells.
138. PMID: 20179210; 2010, Cancer Res;70(5):2064-74
Protein kinase C*iota* is required for pancreatic cancer cell transformed growth and tumorigenesis.
139. PMID: 18234642; 2008, Hepatobiliary Pancreat Dis Int;7(1):70-5
Correlation of aPKC-*iota* and E-cadherin expression with invasion and prognosis of cholangiocarcinoma.
140. PMID: 12888898; 2003, Int J Oncol;23(3):633-9
Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis.
141. PMID: 19805306; 2009, Proc Natl Acad Sci U S A;106(38):16369-74
aPKC*lambda*/*iota* promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6.
142. PMID: 22293180; 2012, J Clin Invest;122(2):425-34
Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.
143. PMID: 6320372; 1984, Science;223(4640):1028-33
Retinoblastoma: clues to human oncogenesis.
144. PMID: 27308386; 2015, Mol Cell Oncol;2(1):e968069
Conditional haploinsufficiency of the retinoblastoma tumor suppressor gene.
145. PMID: 23687339; 2013, Cancer Res;73(14):4247-55
Rb1 haploinsufficiency promotes telomere attrition and radiation-induced genomic instability.
146. PMID: 28169375; 2017, Sci Rep;7():42056
The Rb1 tumour suppressor gene modifies telomeric chromatin architecture by regulating TERRA expression.
147. PMID: 15884040; 2005, Hum Mutat;25(6):566-74
Sensitive multistep clinical molecular screening of 180 unrelated individuals with retinoblastoma detects 36 novel mutations in the RB1 gene.
148. PMID: 26238431; 2015, Eur Urol;68(6):959-67
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
149. PMID: 22811582; 2012, Clin Cancer Res;18(18):5110-22
RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.
150. PMID: 21358261; 2011, Cell Cycle;10(6):956-62

ACT Onco[®] + Report

A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen.

151. PMID: 17160137; 2007, J Clin Invest;117(1):218-28
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
152. PMID: 29236940; 2018, Ann Oncol;29(3):640-645
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
153. PMID: 29483214; 2018, Mol Cancer Ther;17(5):897-907
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
154. PMID: 22941188; 2012, Nat Genet;44(10):1104-10
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
155. PMID: 22941189; 2012, Nat Genet;44(10):1111-6
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.
156. PMID: 25846096; 2015, Lancet Oncol;16(4):e165-72
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.
157. PMID: 25935112; 2015, Trends Biochem Sci;40(6):296-308
Structural determinants of Smad function in TGF- β signaling.
158. PMID: 19014666; 2008, Pathogenetics;1(1):2
Smad4 haploinsufficiency: a matter of dosage.
159. PMID: 9545410; 1998, Am J Hum Genet;62(5):1129-36
A gene for familial juvenile polyposis maps to chromosome 18q21.1.
160. PMID: 8553070; 1996, Science;271(5247):350-3
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.
161. PMID: 8673134; 1996, Nat Genet;13(3):343-6
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers.
162. PMID: 18662538; 2008, Cell;134(2):215-30
TGFbeta in Cancer.
163. PMID: 9135016; 1997, Cancer Res;57(9):1731-4
Tumor-suppressive pathways in pancreatic carcinoma.
164. PMID: 23139211; 2013, Cancer Res;73(2):725-35
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.
165. PMID: 22810696; 2012, Nature;487(7407):330-7
Comprehensive molecular characterization of human colon and rectal cancer.
166. PMID: 25890228; 2015, World J Surg Oncol;13():128
Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study.
167. PMID: 19841540; 2009, J Clin Invest;119(11):3208-11
Smad4: gatekeeper gene in head and neck squamous cell carcinoma.
168. PMID: 15867212; 2005, Clin Cancer Res;11(9):3191-7
Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma.
169. PMID: 25589618; 2015, Clin Cancer Res;21(6):1447-56
Genomic analysis of metastatic cutaneous squamous cell carcinoma.

ACT Onco[®] + Report

170. PMID: 29703253; 2018, BMC Cancer;18(1):479
SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
171. PMID: 28522603; 2017, Clin Cancer Res;23(17):5162-5175
SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.
172. PMID: 16144935; 2005, Clin Cancer Res;11(17):6311-6
SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
173. PMID: 24384683; 2014, Br J Cancer;110(4):946-57
Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
174. PMID: 12237773; 2002, Br J Cancer;87(6):630-4
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.
175. PMID: 25749173; 2015, Transl Oncol;8(1):18-24
A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer.
176. PMID: 19478385; 2009, Cell Oncol;31(3):169-78
Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.
177. PMID: 25681512; 2015, J Clin Pathol;68(5):341-5
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
178. PMID: 26861460; 2016, Clin Cancer Res;22(12):3037-47
Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.
179. PMID: 26947875; 2016, Transl Oncol;9(1):1-7
Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis.
180. PMID: 25760429; 2015, Pancreas;44(4):660-4
SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
181. PMID: 22504380; 2012, Pancreas;41(4):541-6
SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.
182. PMID: 19584151; 2009, Clin Cancer Res;15(14):4674-9
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.
183. PMID: 18425078; 2008, Mod Pathol;21(7):866-75
Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival.
184. PMID: 21332640; 2011, J Cell Mol Med;15(7):1433-42
Targeting telomerase-expressing cancer cells.
185. PMID: 19571879; 2009, Nature;460(7251):66-72
Telomerase modulates Wnt signalling by association with target gene chromatin.
186. PMID: 23159929; 2012, Nat Cell Biol;14(12):1270-81
Telomerase directly regulates NF- κ B-dependent transcription.
187. PMID: 19701182; 2009, Nature;461(7261):230-5
An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA.
188. PMID: 23348506; 2013, Science;339(6122):957-9
Highly recurrent TERT promoter mutations in human melanoma.
189. PMID: 23530248; 2013, Proc Natl Acad Sci U S A;110(15):6021-6
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

ACT Onco[®] + Report

190. PMID: 11103775; 2000, Cancer Res;60(22):6230-5
Frequent amplification of the telomerase reverse transcriptase gene in human tumors.
191. PMID: 12007187; 2002, Genes Chromosomes Cancer;34(3):269-75
Amplification of the telomerase reverse transcriptase (hTERT) gene in cervical carcinomas.
192. PMID: 25301727; 2014, Oncotarget;5(20):10048-57
TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma.
193. PMID: 16641908; 2006, Br J Cancer;94(10):1452-9
Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer.
194. PMID: 27982019; 2017, Cancer Gene Ther;24(1):20-27
The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.
195. PMID: 29100407; 2017, Oncotarget;8(44):77540-77551
TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer.
196. PMID: 26156651; 2015, Lancet Oncol;16(8):897-907
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
197. PMID: 23816960; 2013, J Clin Oncol;31(27):3327-34
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
198. PMID: 22285168; 2012, Lancet Oncol;13(3):239-46
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EORTAC): a multicentre, open-label, randomised phase 3 trial.
199. PMID: 17452677; 2007, J Clin Oncol;25(15):1960-6
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
200. PMID: 26703889; 2016, Lancet;387(10022):968-977
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
201. PMID: 22149876; 2012, N Engl J Med;366(6):520-9
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
202. PMID: 21306238; 2011, N Engl J Med;364(6):514-23
Everolimus for advanced pancreatic neuroendocrine tumors.
203. PMID: 23158522; 2013, Lancet;381(9861):125-32
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
204. PMID: 18653228; 2008, Lancet;372(9637):449-56
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
205. PMID: 24263064; 2014, Br J Cancer;110(1):55-62
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
206. PMID: 30948273; 2019, Lancet Oncol;20(5):636-648
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
207. PMID: 27717299; 2016, N Engl J Med;375(22):2154-2164
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

ACT Onco[®] + Report

208. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
209. PMID: 31157963; 2019, N Engl J Med;381(4):317-327
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
210. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
211. PMID: 28578601; 2017, N Engl J Med;377(6):523-533
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
212. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
213. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
214. PMID: 25366685; 2015, J Clin Oncol;33(3):244-50
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
215. PMID: 27959700; 2017, N Engl J Med;376(7):629-640
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
216. PMID: 27908594; 2017, Lancet Oncol;18(1):75-87
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
217. PMID: 30110579; 2018, N Engl J Med;379(8):753-763
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
218. PMID: 17538086; 2007, N Engl J Med;356(22):2271-81
Temsilolimus, interferon alfa, or both for advanced renal-cell carcinoma.